More Alterity Therapeutics Ltd. news
Alterity Therapeutics Ltd.ASX: ATH

US patent for next generation neurodegenerative diseases

Nov 15, 2020 at 10:58 PM EST · Issued by Alterity Therapeutics Ltd.

Filed with ASX · Nov 15, 2020 at 10:58 PM EST

On 6ix: 6ix.com/news/us-patent-for-next-generation-neurodegenerative-diseases

Alterity Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Alterity Therapeutics Ltd. on 6ix

In the deck

  • Alterity Therapeutics — Shareholder Meeting (November 2020)27 slidesNov 18, 2020

Story so far

  • Meeting with US FDA provides development path for ATH434Jun 30, 2020

Earlier from Alterity Therapeutics

  • MSA patients enrolled in bioMUSE StudyOct 26, 2020
  • Alterity completes Placement Tranche 1 raising $10MOct 23, 2020
  • Alterity raises $35M in placement to institutional investorsOct 15, 2020
  • Company update on Annual Report 2020Sep 9, 2020
  • Preliminary Final ReportAug 30, 2020

Later from Alterity Therapeutics

  • Chairmans Address 2020 Annual General MeetingNov 17, 2020
  • Prospectus filed pursuant to SEC Rule 424(b)(3)Nov 24, 2020
  • Alterity presents at Finance News NetworkDec 1, 2020
  • New commercial opportunity for PBT2Dec 21, 2020
  • Form F-3Dec 23, 2020
All Alterity Therapeutics news releases↗

Follow Alterity Therapeutics into a list and get an email when it puts out news.

Follow Alterity Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer